ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO371

Promoting Mitochondrial Dynamics by Inhibiting the PINK1/PRKN Pathway to Relieve Diabetic Nephropathy

Session Information

Category: Diabetic Kidney Disease

  • 701 Diabetic Kidney Disease: Basic

Author

  • Zhu, Junyi, University of Maryland Baltimore, Baltimore, Maryland, United States
Background

Diabetes is a metabolic disorder characterized by high blood glucose levels and a leading cause of kidney disease. Dysfunctional mitochondria have been associated with diabetic nephropathy. However, many questions remain about the exact mechanism; its understanding is important to develop effective therapeutics.

Methods

Structure, function, and molecular pathways are highly conserved between mammalian podocytes and Drosophila nephrocytes Thus we used flies on a high sucrose diet to model type 2 diabetic nephropathy. We then investigated the structural and functional effects on the fly nephrocytes and their mitochondria.

Results

The nephrocytes of flies on a high sucrose diet showed remarkable levels of functional decline and decreased cell size; the flies had a shortened lifespan. Structurally, the slit diaphragm—nephrocyte filtration structure—was disorganized. At the cellular level, we found altered mitochondrial dynamics and dysfunction. Regulating mitochondrial dynamics by either genetic modification of the Pink1/Park (mammalian PINK1/PRKN) pathway or treatment with BGP-15, mitigated the mitochondrial defects and nephrocyte functional decline.

Conclusion

These findings support a role for Pink1/Park-mediated mitophagy and associated control of mitochondrial dynamics and health in diabetic nephropathy; and demonstrate that targeting this pathway might provide therapeutic benefits in type 2 diabetic nephropathy.

Funding

  • Private Foundation Support